tbuckley/cabot-search huggingface dataset:
Gender-related differences in left ventricular chamber function
Authors: C Hayward
Journal: Cardiovascular Research (2001)

Objectives: While women have lower rates of atherosclerotic disease than men, they are more likely to suffer cardiac failure following infarction or cardiac surgery, despite typically having a greater left ventricular (LV) ejection fraction. We hypothesised that gender differences in systolic chamber function and ventriculo-vascular coupling may contribute to these clinical findings. Methods: LV chamber function was determined in a cohort of 30 patients (16 women) aged 48–75 years with normal LV function using pressure-volume loops obtained by simultaneous conductance catheter volumetry and micromanometer pressure. End-systolic and end-diastolic pressure volume (ESPVR, EDPVR) and preload recruitable stroke work relations (PRSWR) were derived. Results were analysed according to gender, and the effects of body size and chamber dimensions were examined. Results: The groups were closely matched for age (60±6 vs. 60±8 years) and co-morbid conditions. Women had higher end-systolic blood pressure (139.7±21.1 vs. 123.6±12.6 mmHg, P = 0.001), and smaller LV cavity volume (end-diastolic volume 96.4±30.6 vs. 139±30.7 ml, P = 0.001). Women had significantly higher LV end-systolic elastance (Ees, 2.65±0.10 vs. 1.96±0.09 mmHg ml−1, P<0.002), arterial elastance (2.41±1.13 vs. 1.54±0.55 mmHg ml−1, P = 0.01) and lower passive LV diastolic compliance (slope EDPVR, 6.12±0.37 vs. 10.0±0.50 ml mmHg−1, P<0.001). While there was a strong relationship between end-systolic elastance and chamber volume (r = 0.69, P<0.001), gender differences in chamber function all persisted after indexing to body size. Higher LV systolic function in women was also shown in PRSWR analysis (slope, MSW; 101.4±3.8 vs. 90.4±2.8 mmHg, P<0.05), which is independent of chamber size. After normalising volumes to resting diastolic volume, the greater systolic and diastolic elastance in women was accounted for. The ratio of end-systolic to arterial elastance, a measure of ventriculo-vascular coupling, was similar in women and men (1.19±0.40 vs. 1.54±0.30, respectively, P = 0.23). Conclusions: This study demonstrates greater systolic chamber function and lower diastolic compliance in women. Within the range of chamber dimensions seen in patients with normal LV function, a strong relationship was found between cardiac size and end-systolic elastance. While these differences were not accounted for by indexing to body size, the greater ventricular elastance in women was removed after normalising to chamber size. Despite differences in resting ventricular elastance, appropriate ventriculo-vascular coupling was maintained in both genders as the greater end-systolic elastance in women was matched by similarly elevated arterial elastance.
MMR uptake data are unlikely to be subject to manipulation
Authors: M. Ramsay
Journal: BMJ (2002)

EDITOR—Scanlon suggested that uptake of measles, mumps, and rubella (MMR) vaccine is lower than reported because of manipulation of target groups by general practitioners.1 The figure of 84% quoted, however, comes from the national “coverage of vaccination evaluated rapidly” scheme.2 These data derive from computerised child health registers in each health authority and not from target payments.3

The denominator includes all children who are resident on the last day of each quarter, regardless of whether they are registered with a general …
Health Information Technology in the Era of Care Delivery Reform
Authors: Asaf Bitton, Lydia A. Flier, Ashish K. Jha
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Authors: Peter L. Greenberg, Zhuoxin Sun, Kenneth B. Miller, John M. Bennett, Martin S. Tallman, Gordon Dewald, Elisabeth Paietta, Richard van der Jagt, Jessie Houston, Mary L. Thomas, David Cella, Jacob M. Rowe
Journal: Blood (2009)
Poor Medical Records
Authors: Eric S. Marks
Journal: Annals of Internal Medicine (1989)

Letters and Corrections15 June 1989Poor Medical RecordsEric S. Marks, MDEric S. Marks, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-12-1037_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: My understanding of Dr. Burnum's article (1) is that most inadequacies of the medical record are interpreted as caused by pressures from society and regulatory agencies. I believe that with a few notable exceptions, the primary problem is a lack of writing skills by physicians and other health care providers.The medical chart is intended to record accurately the diagnostic logic used in the care of the patient including observation, description, interpretation, and verification. Even though diagnosis-related groups and related criteria guidelines are relatively strict, the rational approach to diagnosis and treatment does not require a "flood"...References1. Burnum J. The misinformation era: the fall of the medical record. Ann Intern Med. 1989;110:482-4. LinkGoogle Scholar2. Yanoff K and Burg F. Types of medical writing and teaching of writing in U.S. medical schools. J Med Educ. 1988;63:30-7. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Eric S. Marks, MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 June 1989Volume 110, Issue 12Page: 1037-1037KeywordsChartsDiagnosis related groupsHealth care providersPatientsTreatment guidelines ePublished: 1 December 2008 Issue Published: 15 June 1989 PDF downloadLoading ...
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease
Authors: Claire Booth, Kimberly C. Gilmour, Paul Veys, Andrew R. Gennery, Mary A. Slatter, Helen Chapel, Paul T. Heath, Colin G. Steward, Owen Smith, Anna O'Meara, Hilary Kerrigan, Nizar Mahlaoui, Marina Cavazzana-Calvo, Alain Fischer, Despina Moshous, Stephane Blanche, Jana Pachlopnik Schmid, Sylvain Latour, Genevieve de Saint-Basile, Michael Albert, Gundula Notheis, Nikolaus Rieber, Brigitte Strahm, Henrike Ritterbusch, Arjan Lankester, Nico G. Hartwig, Isabelle Meyts, Alessandro Plebani, Annarosa Soresina, Andrea Finocchi, Claudio Pignata, Emilia Cirillo, Sonia Bonanomi, Christina Peters, Krzysztof Kalwak, Srdjan Pasic, Petr Sedlacek, Janez Jazbec, Hirokazu Kanegane, Kim E. Nichols, I. Celine Hanson, Neena Kapoor, Elie Haddad, Morton Cowan, Sharon Choo, Joanne Smart, Peter D. Arkwright, Hubert B. Gaspar
Journal: Blood (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Authors: Sharmila Makhija, Lukas C. Amler, Dana Glenn, Frederick R. Ueland, Michael A. Gold, Don S. Dizon, Virginia Paton, Chin-Yu Lin, Thomas Januario, Kimmie Ng, Andreas Strauss, Stephen Kelsey, Mark X. Sliwkowski, Ursula Matulonis
Journal: Journal of Clinical Oncology (2009)

Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has single-agent activity in recurrent epithelial ovarian cancer. The primary objective of this phase II study was to characterize the safety and estimate progression-free survival (PFS) of pertuzumab with gemcitabine in patients with platinum-resistant ovarian cancer.Patients with advanced, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received a maximum of one prior treatment for recurrent cancer were randomly assigned to gemcitabine plus either pertuzumab or placebo. Collection of archival tissue was mandatory to permit exploration of biomarkers that would predict benefit from pertuzumab in this setting.One hundred thirty patients (65 per arm) were treated. Baseline characteristics were similar between arms. The adjusted hazard ratio (HR) for PFS was 0.66 (95% CI, 0.43 to 1.03; P = .07) in favor of gemcitabine + pertuzumab. The objective response rate was 13.8% in patients who received gemcitabine + pertuzumab compared with 4.6% in patients who received gemcitabine + placebo. In patients whose tumors had low HER3 mRNA expression (< median, n = 61), an increased treatment benefit was observed in the gemcitabine + pertuzumab arm compared with the gemcitabine alone arm (PFS HR = 0.32; 95% CI, 0.17 to 0.59; P = .0002). Grade 3 to 4 neutropenia, diarrhea, and back pain were increased in patients treated with gemcitabine + pertuzumab. Symptomatic congestive heart failure was reported in one patient in the gemcitabine + pertuzumab arm.Pertuzumab may add activity to gemcitabine for the treatment of platinum-resistant ovarian cancer. Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic marker.
The Patient-Physician Relation: The Patient as Partner, Part 2
Authors: Stanley J. Reiser
Journal: JAMA (1992)

This work by Robert Veatch is a collection of his essays (most already published, others written for it), which are brought together by their focus on the clinical relationship between physicians and patients. It is a companion volume to<i>The Patient as Partner: A Theory of Human-Experimentation Ethics</i>(Indiana University Press, 1987), which examined research in medicine. The subjects explored are important and varied. Essays appear on doctors as strangers, principles of medical ethics, informed consent, deciding what patients should know, prescribing placebos, duties of patients, cost-containment, risk-taking behavior, transplantation, guardianship, do-not-resuscitate orders, and institutional ethics committees. This list reveals the breadth of the book, which provides a wealth of commentary on central issues in medical ethics. This breadth also is a source of weakness. The essays, written at different times for different audiences, though often connected by newly written transitional paragraphs, nevertheless do not create a coherent whole. This
Painful piezogenic pedal papules
Authors: R.R.M. HARMAN, CYNTHIA N.A. MATTHEWS
Journal: British Journal of Dermatology (1974)

Journal Article Painful piezogenic pedal papules Get access R.R.M. HARMAN, R.R.M. HARMAN Department of Dermatology, United Bristol Hospitals, Royal Infirmary Branch, Bristol BS2 8HW Search for other works by this author on: Oxford Academic Google Scholar CYNTHIA N.A. MATTHEWS CYNTHIA N.A. MATTHEWS Department of Dermatology, United Bristol Hospitals, Royal Infirmary Branch, Bristol BS2 8HW Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 90, Issue 5, 1 May 1974, Pages 573–574, https://doi.org/10.1111/j.1365-2133.1974.tb06455.x Published: 01 May 1974 Article history Accepted: 14 August 1973 Published: 01 May 1974
The ???Pseudo-Pseudoaneurysm??? Left Ventricular Pseudoaneurysm Mimicked by Ectopic Spleen
Authors: S GOLDWAG, R J CAMPEAU, M AGASALA, G KARCIOGLU
Journal: Clinical Nuclear Medicine (1994)

Extracardiac accumulation of labeled red cells was noted on a gated equilibrium blood pool study. The appearance and location of radiotracer mimicked a left ventricular pseudoaneurysm. Echocardiography failed to reveal a “neck” or an extraventricular sac, and there was excellent posterolateral left ventricular wall motion. Previously obtained plain radiographs and CT images of the chest were reviewed. An elevated left hemidiaphragm associated with superior displacement of the spleen accounted for the extracardiac radiolabeled red cells.
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Authors: Shahab Uddin, Azhar R. Hussain, Abdul K. Siraj, Pulicat S. Manogaran, Naif A. Al-Jomah, Azadali Moorji, Valerie Atizado, Fouad Al-Dayel, Asim Belgaumi, Hassan El-Solh, Adnan Ezzat, Prashant Bavi, Khawla S. Al-Kuraya
Journal: Blood (2006)
Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity.
Authors: T Matsumura, K Kugiyama, S Sugiyama, M Ohgushi, K Amanaka, M Suzuki, H Yasue
Journal: Journal of Clinical Investigation (1996)

This study was performed to determine effects of atrial and brain natriuretic peptides (ANP, BNP) on neutrophils-induced endothelial injury which is known to play a role in the pathophysiology of ischemia/reperfusion myocardial injury and to examine whether the effects of ANP and BNP on neutrophils are modulated by neutral endopeptidase 24.11 (NEP) in neutrophils themselves. The incubation of human neutrophils with ANP and BNP inhibited the neutrophils-induced detachment of cultured human endothelial cells (HEC). The inhibitory effect of ANP and BNP was associated with the suppressions of the neutrophils adhesiveness to HEC, CD18 expression on the neutrophils and elastase release from the neutrophils. Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils. NEP enzymatic activity in the particulate fractions and immunoreactive NEP expression were found to increase in the neutrophils from patients with early phase of acute myocardial infarction (AMI) by 5.2- and by 4.2-fold of the neutrophils from patients with late phase of AMI, respectively. In an in vivo canine model of myocardial ischemia/reperfusion, the intravenous administration of UK73967 suppressed the neutrophil adherence to endothelium and the neutrophil accumulation in the ischemic/reperfused myocardium. The results indicate that ANP and BNP, which are known to increase in AMI, modulate the neutrophil functions and exert protective effects against the neutrophils-induced endothelial cytotoxity. But the effects are suppressed due to their degradation by the neutrophil own NEP. Thus, neutrophil NEP, which also increases in AMI, may play a role in the pathophysiology of neutrophils-mediated ischemia/reperfusion endothelial and myocardial injury.
Review rejects claim of higher hospital death rates in England than in US
Authors: J. Wise
Journal: BMJ (2015)

Hospital standardised mortality ratios (HSMRs) are an unreliable method for comparing the quality of hospitals in the United States and England, an investigation by the Academy of Medical Royal Colleges has concluded.1

The independent inquiry was commissioned after Brian Jarman, former professor of primary care at Imperial College London, who developed the HSMR index, said in media reports in September 2013 that the likelihood of dying in NHS hospitals in England was 45% higher than in hospitals in the United States.2 His claim, made on Channel 4 news and repeated in many newspapers, came soon after 11 hospitals had been put into special measures and shortly after Robert Francis QC’s report into failings in care at Staffordshire Hospital.

Jarman’s HSMR is the actual number of deaths at a hospital divided by the expected number of deaths over the same period, multiplied by 100. Scores are published annually in the Hospital Guide produced by the …
Funding gap threatens to stall progress on polio eradication
Authors: A. Gulland
Journal: BMJ (2012)

A funding shortage of nearly $1bn threatens to undermine efforts to eradicate polio worldwide, warns a report by a body that monitors progress on the disease.

The World Health Organization set up an independent monitoring board to report on the progress of its global polio eradication initiative. Its report says that polio is at its lowest level since records began and that 52 cases were reported in the first four months of this year, less than half the 123 reported in the same period last year.1

The report also highlights the “magnificent achievement” in India, which WHO declared free of polio in February.2 The former chief medical officer for England, Liam Donaldson, chairman of the …
Textbook of Gynecology
Authors: A. Brian Little
Journal: JAMA (1977)

The preface states that this is a "reference text for physicians who deal with the gynecologic patient" plus "authoritative papers... to serve the requirements of the gynecologic specialist." Unfortunately, because of its unevenness, this text fails to satisfy these proposed objectives. The contributors are an extremely varied group, ranging from acknowledged scientists and clinicians to unknown authors. Perhaps we can imagine the harried editor trying first to capture contributors at meetings, then falling back on his own present and former faculty, and finally realizing, as the deadline approaches, that his fill-in contributors have failed to reach his standards or objectives. Strong editing does not appear to have taken place in this text. This in no way detracts from some of the individual contributions: after reading both William Ledger on infections and infestations of the lower genital tract and Roger Kempers on the menopause, I was extremely encouraged. Both had written
Prognostic Relevance of 18F-FDG PET/CT in Carcinoma of Unknown Primary
Authors: Niklas Breuer, Florian F. Behrendt, Alexander Heinzel, Felix M. Mottaghy, Moritz Palmowski, Frederik A. Verburg
Journal: Clinical Nuclear Medicine (2013)

The aim of this study was to assess whether F-FDG PET combined with x-ray CT (F-FDG PET/CT) findings have a prognostic impact in patients with carcinoma of unknown primary (CUP).Seventy patients with CUP who were referred for F-FDG PET/CT were included. F-FDG PET/CT results were checked against available histologic diagnosis and follow-up data. For each patient, the SUVmax of the lesion with maximum uptake was measured.In 26% of the patients, a primary tumor was identified. The follow-up period after F-FDG PET/CT scan ranged between 3 and 45 months. Kaplan-Meier analysis revealed 1-year survival rates of 92% in the group without evidence of malignancy on F-FDG PET/CT, 78% in the group with locoregional disease, and 34% in the group with extensive disease on F-FDG PET/CT. Three-year survival rates in these groups were 73%, 71%, and 23%, respectively (P = 0.001). There was no significant survival difference between patients with regionally confined disease without identification of the primary tumor and those in whom the primary tumor was identified on F-FDG PET/CT (P = 0.25). This was also the case for patients with extensive disease (P = 0.26). The SUVmax of the lesion with maximum uptake was not significantly related to survival (P = 0.56).F-FDG PET/CT is a helpful tool for the identification of the primary tumor in patients with CUP; it is also able to provide an accurate assessment of prognosis based on the extent of the disease without the need for identification of the primary tumor.
Ulcerative Colitis Beginning in Childhood
Authors: Sidney C. Truelove
Journal: New England Journal of Medicine (1971)

Ulcerative colitis is not frequent in childhood, but there is a general clinical impression that, when it does occur in children, it frequently runs a severe course. It is therefore valuable to have the sort of study on prognosis reported by Devroede and his colleagues in this number of the Journal (p 17). It is a measure of the wealth of clinical experience at the Mayo Clinic that the authors have been able to assemble no fewer than 396 subjects seen while children at the Clinic from 1919 to 1965 in whom the diagnosis of ulcerative colitis was firm. The . . .
Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis
Authors: J. Leipe, M. A. Schramm, M. Grunke, M. Baeuerle, C. Dechant, A. P. Nigg, M. N. Witt, V. Vielhauer, C. S. Reindl, H. Schulze-Koops, A. Skapenko
Journal: Annals of the Rheumatic Diseases (2011)

To study the role of interleukin 22 (IL-22) in rheumatoid arthritis (RA).IL-22 serum levels were measured in patients with early, treatment-naive RA (n=49) and in 45 age- and sex-matched healthy individuals as controls. Patients were assessed clinically and radiographically at baseline and followed up for 2 years. Correlations of IL-22 serum levels were sought with parameters of disease activity, serological markers, demographic factors and the incidence of erosions. IL-22 production by peripheral blood T cells was investigated by intracellular flow cytometry.24 of 49 patients with RA demonstrated elevated IL-22 levels compared with the range of healthy controls. At baseline, a high percentage of these patients (8/24, 33%) demonstrated bone erosions, whereas only one patient (4%) from the group with normal IL-22 had erosions. During the 2 years of follow-up, six additional patients with increased IL-22 at baseline developed erosions. In contrast, none of the patients in whom IL-22 levels were normal developed erosions despite similar treatment regimens. Multivariate regression analysis accounting for other parameters predictive for erosions, such as the presence of rheumatoid factor or anti-cyclic citrullinated peptide antibodies and disease activity, showed that elevated IL-22 baseline levels were independently and significantly associated with erosive RA. Cellular analysis demonstrated enhanced expression of IL-22 from CD4 T cells in RA.IL-22 is elevated in the serum of half of the patients with RA. Elevated serum IL-22 allows discrimination between patients with different radiographic progression and indicates a possible involvement of IL-22 in the pathophysiology of RA.